ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company focused on women's reproductive health, will present a corporate update at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This presentation will be available on-demand starting at 7 a.m. EST on January 10.

A webcast can be accessed through the conference portal and will also be available on ObsEva's website from January 14, 2022. ObsEva is developing therapies for uterine fibroids, endometriosis, and preterm labor.

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022.

A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website, starting Friday, January 14, 2022.

 

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

 

For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

 

 

 

Attachment

• Press Release in Pdf

FAQ

When will ObsEva present at the H.C. Wainwright BioConnect Conference?

ObsEva will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

How can I access the ObsEva corporate update presentation?

The ObsEva corporate update presentation will be available on-demand through the H.C. Wainwright conference portal starting at 7 a.m. EST on January 10, 2022.

Where can I find the webcast of the ObsEva presentation?

The webcast will be accessible on the H.C. Wainwright conference portal and on ObsEva's website under the 'Events Calendar' from January 14, 2022.

What does ObsEva focus on in its development programs?

ObsEva focuses on developing therapies for women's reproductive health, specifically targeting uterine fibroids, endometriosis, and preterm labor.